Trial Profile
A study evaluating early PSA response to Enzalutamide treatment for Japanese patients with metastatic castration-resistant prostate cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2020
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Docetaxel
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 27 Oct 2017 New trial record